Literature DB >> 7595701

Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: the causative role of improper dissolution of Cremophor EL.

J G Theis1, M Liau-Chu, H S Chan, J Doyle, M L Greenberg, G Koren.   

Abstract

PURPOSE: An unusually high incidence of anaphylactoid reactions was observed during a phase I/II trial of high-dose intravenous cyclosporine (CsA) therapy to attenuate tumor multidrug resistance (MDR). Five of 21 children experienced severe anaphylactoid reactions shortly after initiation of the first or second CsA infusion. We hypothesized that improper dissolution of the vehicle Cremophor EL may have been a cause for these anaphylactoid reactions.
METHODS: All nurses who had administered intravenous CsA were interviewed regarding their technique of preparing the infusion and the occurrence of an anaphylactoid reaction. The responses were statistically analyzed. The effect of various mixing techniques on the distribution of Cremophor EL in the infusion was experimentally evaluated. Different mixing techniques were used to assess their effect on the distribution of Cremophor EL in the solution.
RESULTS: Analysis of the preparation techniques of the CsA infusion showed significant correlation between suboptimal mixing of CsA by nurses and the occurrence of anaphylactoid reactions (P = .02). Experimental simulation showed that suboptimal mixing results in an uneven distribution of Cremophor EL, which subsequently sinks to the bottom of the vial.
CONCLUSION: Improper mixing of high-dose CsA infusions causes nonsolubilized Cremophor EL to sink to the outflow area of the bottle. An initial bolus infusion of highly concentrated Cremophor EL may produce an anaphylactoid-like response. This mechanism of toxicity is important to recognize, because it is easily preventable by proper preparation of the infusion, thus reducing the incidence of potentially life-threatening anaphylactoid reactions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7595701     DOI: 10.1200/JCO.1995.13.10.2508

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  7 in total

Review 1.  Long acting systemic HIV pre-exposure prophylaxis: an examination of the field.

Authors:  William R Lykins; Ellen Luecke; Daniel Johengen; Ariane van der Straten; Tejal A Desai
Journal:  Drug Deliv Transl Res       Date:  2017-12       Impact factor: 4.617

Review 2.  Multidrug resistance in pediatric oncology.

Authors:  J F Kuttesch
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 3.  Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.

Authors:  Albert J ten Tije; Jaap Verweij; Walter J Loos; Alex Sparreboom
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

4.  Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study.

Authors:  F Doz; J C Gentet; F Pein; D Frappaz; P Chastagner; S Moretti; G Vassal; J Arditti; O V Tellingen; A Iliadis; J Catalin
Journal:  Br J Cancer       Date:  2001-03-02       Impact factor: 7.640

5.  Effects of Adamantyl Derivatives on Pharmacokinetic Behavior of Paclitaxel in Rats.

Authors:  Kyung Mi Kim; Kyeong Lee; Kyusic Jang; Yae Seul Moon; Hwa Jeong Lee; Sandy Jeong Rhie
Journal:  Biomol Ther (Seoul)       Date:  2017-09-01       Impact factor: 4.634

6.  Bioequivalence and tolerability assessment of a novel intravenous ciclosporin lipid emulsion compared to branded ciclosporin in Cremophor ® EL.

Authors:  Karl Henrik Johannes Ehinger; Magnus Joakim Hansson; Fredrik Sjövall; Eskil Elmér
Journal:  Clin Drug Investig       Date:  2013-01       Impact factor: 2.859

7.  High-dose cyclosporin with etoposide--toxicity and pharmacokinetic interaction in children with solid tumours.

Authors:  G Bisogno; F Cowie; A Boddy; H D Thomas; G Dick; C R Pinkerton
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.